Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01981837
Recruitment Status : Completed
First Posted : November 13, 2013
Last Update Posted : January 29, 2018
Sponsor:
Information provided by (Responsible Party):
Alnylam Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : October 2014
  Actual Study Completion Date : January 2015
  Certification/Extension First Submitted : January 24, 2018